New pill aims to shrink Hard-to-Treat cancers
NCT ID NCT07029399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors, either alone or with other drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NKT5097 (oral tablet that degrades CDK2 and CDK4 proteins)
- What this could lead to
- If it works, this could lead to a new treatment option for advanced breast cancer and other solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and it will take years to know if it helps patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
-
Comprehensive Cancer Centers of Nevada
RECRUITINGLas Vegas, Nevada, 89169, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
SCRI Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics (START) Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
South Texas Accelerated Research Therapeutics (START) San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92037, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Email: •••••@•••••
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
West Virginia University
RECRUITINGMorgantown, West Virginia, 26506, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- What raises endometrial cancer risk in black women? a study digs in
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Tumor DNA mapping may unlock personalized cancer therapies